Literature DB >> 11237521

PTEN: life as a tumor suppressor.

L Simpson1, R Parsons.   

Abstract

PTEN, a tumor suppressor located at chromosome 10q23, is mutated in a variety of sporadic cancers and in two autosomal dominant hamartoma syndromes. PTEN is a phosphatase which dephosphorylates phosphatidylinositol (3,4,5)-triphosphate (PtdIns-3,4,5-P3), an important intracellular second messenger, lowering its level within the cell. By dephosphorylating PtdIns-3,4,5-P3, PTEN acts in opposition to phosphatidylinositol 3-kinase (PI3K), which has a pivotal role in the creation of PtdIns-3,4,5-P3. PtdIns-3,4,5-P3 is necessary for the activation of Akt, a serine/threonine kinase involved in cell growth and survival. By blocking the activation of Akt, PTEN regulates cellular processes such as cell cycling, translation, and apoptosis. In this review, we will discuss the identification of PTEN, its mutational status in cancer, its role as a regulator of PI3K, and its domain structure. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11237521     DOI: 10.1006/excr.2000.5130

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  183 in total

1.  Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

Authors:  G B Mills; Y Lu; E C Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 2.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

3.  Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility.

Authors:  Chunmei C Xie; Lingyi Lu; Jielin Sun; S Lilly Zheng; William B Isaacs; Henrik Gronberg; Jianfeng Xu
Journal:  J Hum Genet       Date:  2011-06-02       Impact factor: 3.172

4.  Systemic elevation of PTEN induces a tumor-suppressive metabolic state.

Authors:  Isabel Garcia-Cao; Min Sup Song; Robin M Hobbs; Gaelle Laurent; Carlotta Giorgi; Vincent C J de Boer; Dimitrios Anastasiou; Keisuke Ito; Atsuo T Sasaki; Lucia Rameh; Arkaitz Carracedo; Matthew G Vander Heiden; Lewis C Cantley; Paolo Pinton; Marcia C Haigis; Pier Paolo Pandolfi
Journal:  Cell       Date:  2012-03-06       Impact factor: 41.582

5.  Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage.

Authors:  Eugene S Kandel; Jennifer Skeen; Nathan Majewski; Antonio Di Cristofano; Pier Paolo Pandolfi; Claudine S Feliciano; Andrei Gartel; Nissim Hay
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

6.  Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis.

Authors:  Susumu Rokudai; Naoya Fujita; Osamu Kitahara; Yusuke Nakamura; Takashi Tsuruo
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

Review 7.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

8.  Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.

Authors:  Andreas G Bader; Peter K Vogt
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

9.  MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis.

Authors:  Junchao Cai; Hongyu Guan; Lishan Fang; Yi Yang; Xun Zhu; Jie Yuan; Jueheng Wu; Mengfeng Li
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

10.  Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.

Authors:  Piotr G Rychahou; JungHee Kang; Pat Gulhati; Hung Q Doan; L Andy Chen; Shu-Yuan Xiao; Dai H Chung; B Mark Evers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.